{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:10:18Z","timestamp":1787155818769,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873759"],"award-info":[{"award-number":["81873759"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.msard.2022.103526","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T01:15:50Z","timestamp":1642036550000},"page":"103526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Clinical analysis of myelin oligodendrocyte glycoprotein antibody\u2013associated demyelination in children: A single-center cohort study in China"],"prefix":"10.1016","volume":"58","author":[{"given":"Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2022.103526_bib0001","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1756285611433772","article-title":"Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more","volume":"5","author":"Mayer","year":"2012","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"21","key":"10.1016\/j.msard.2022.103526_bib0002","doi-asserted-by":"crossref","first-page":"E1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults The MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2022.103526_bib0003","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00415-018-8781-3","article-title":"MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein","volume":"265","author":"Baumann","year":"2018","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2022.103526_bib0004","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Multiple Sclerosis J."},{"issue":"2","key":"10.1016\/j.msard.2022.103526_bib0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2022.103526_bib0006","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nature Rev. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.103526_bib0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0037-1604404","article-title":"MOG spectrum disorders and role of MOG-antibodies in clinical practice","volume":"49","author":"Hennes","year":"2018","journal-title":"Neuropediatrics"},{"issue":"2","key":"10.1016\/j.msard.2022.103526_bib0008","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nature Rev. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2022.103526_bib0009","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Multiple Sclerosis J."},{"issue":"10","key":"10.1016\/j.msard.2022.103526_bib0010","doi-asserted-by":"crossref","first-page":"8985","DOI":"10.1074\/jbc.M413174200","article-title":"Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein - Potential implications for multiple sclerosis","volume":"280","author":"Marta","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.msard.2022.103526_bib0011","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2018.05.014","article-title":"Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: a multicenter study in South China","volume":"321","author":"Chen","year":"2018","journal-title":"J. Neuroimmunol."},{"issue":"17","key":"10.1016\/j.msard.2022.103526_bib0012","doi-asserted-by":"crossref","first-page":"7990","DOI":"10.1073\/pnas.90.17.7990","article-title":"Myelin\/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex","volume":"90","author":"Pham-Dinh","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.msard.2022.103526_bib0013","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2022.103526_bib0014","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment approaches for MOG-Ab-associated demyelination in children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.103526_bib0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ene.13791","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated demyelination: comparison between onset phenotypes","volume":"26","author":"Zhou","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.103526_bib0016","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dmcn.14032","article-title":"Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children","volume":"61","author":"Ramanathan","year":"2019","journal-title":"Dev. Med. Child Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.103526_bib0017","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000062","article-title":"Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?","volume":"2","author":"Zamvil","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2022.103526_bib0018","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.103526_bib0019","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1212\/WNL.0000000000004117","article-title":"Diagnostic algorithm for relapsing acquired demyelinating syndromes in children","volume":"89","author":"Hacohen","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2022.103526_bib0020","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2022.103526_bib0021","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/dmcn.13649","article-title":"Leukodystrophy-like' phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"60","author":"Hacohen","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.103526_bib0022","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2022.103526_bib0023","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflammation"},{"issue":"20","key":"10.1016\/j.msard.2022.103526_bib0024","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008479","article-title":"Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases","volume":"93","author":"Mariotto","year":"2019","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.msard.2022.103526_bib0025","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009239","article-title":"Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies","volume":"94","author":"Martinez-Hernandez","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2022.103526_bib0026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neuron.2006.03.026","article-title":"NMDA receptors, glial cells, and clinical medicine","volume":"50","author":"Lipton","year":"2006","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.msard.2022.103526_bib0027","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti-N-methyl-d-aspartate receptor encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.103526_bib0028","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.103526_bib0029","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti\u2013myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.msard.2022.103526_bib0030","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/dmcn.13703","article-title":"Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes","volume":"60","author":"Duignan","year":"2018","journal-title":"Dev. Med. Child Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822000414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822000414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:00:27Z","timestamp":1761901227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822000414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":30,"alternative-id":["S2211034822000414"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103526","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical analysis of myelin oligodendrocyte glycoprotein antibody\u2013associated demyelination in children: A single-center cohort study in China","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103526"}}